Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP547 in Cholestatic or Uremic Pruritus
NCT04510090Phase 1Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of EP547 in cholestatic pruritus and uremic pruritus (4 arms), sponsored by Escient Pharmaceuticals. Primary endpoint: Incidence of Adverse Events. Started Sep 2020; status: completed.
02
Drugs
EP547
03
Conditions
cholestatic pruritusuremic pruritus
Beyond the preview
Go deeper on NCT04510090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510090.